ArticleCancer biology & therapy2016

EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.

Dan Que et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.